ArthroCare develops and manufactures surgical devices, instruments, and implants that strive to enhance surgical techniques as well as improve patient outcomes. Its devices improve many existing surgical procedures and enable new minimally invasive procedures. Many of ArthroCare's devices use its internationally patented Coblation (R) technology. This technology precisely dissolves target tissue and limits damage to surrounding healthy tissue. ArthroCare also develops surgical devices utilizing other patented technology including its OPUS (R) line of fixation products as well as re-usable surgical instruments. ArthroCare is leveraging these technologies in order to offer a comprehensive line of surgical devices to capitalize on a multi-billion dollar market opportunity across several surgical specialties, including its two core product areas consisting of Sports Medicine and Ear, Nose, and Throat as well as other areas such as spine, wound care, urology and gynecology.

Pulse Therapeutics is a growing medical technology company headquartered in St. Louis, Mo. The medical developer is advancing the fight against stroke, heart disease, and other conditions with its high-level treatment solutions, which utilize the latest biomedical technology and processes. Pulse’s signature offering, the MED System, was designed to harness magnet-based technology to rapidly dissolve blood clots faster than current modalities. This faster rate of delivery of FDA-approved clot-busting medication could dramatically reduce the number of lives lost each year to stroke, heart disease, and other diseases. This pioneering medical development company was founded by leading physicists Francis “Duke” Creighton and Rogers Ritter. Dr. Creighton, who also serves as Pulse’s chief technical officer, has 20-plus years of expertise in the medical technology industry, specializing in the stroke and cardiovascular sectors. He responsible for 30 patents and is a technology reviewer for the National Cancer Institute, National Science Foundation, and National Institutes of Health. The ground-breaking medical solutions of Pulse Therapeutics continues to attract investors and garner media coverage.

Strategic Science & Technologies is a privately-held technology company that focuses on commercializing a novel, patented transdermal administration formula. Its technology is used to formulate known pharmaceutical active ingredients that have a faster onset of action, delivers molecules across the skin in therapeutic areas including pain, and treat sexual disorders that enable physicians to treat various diseases with the support of technology.

Agility Partners develops invasive device therapy for the treatment of congestive heart failure which is inserted into the patient's aorta thus providing significant improvement in blood flow. They provide CHF and H-SAR devices. Their H-SAR device implantable pump inserts through a small hole in the artery using a sheath.

Mars, Inc. engages in the production of confectionery and animal food products. Its brands include M&M?s, Snickers, Twix, Milky Way, Dove, Pedigree, Whiskas, Extra, Skittles, Uncle Ben's, and Cocoavia. The company was founded by Franklin Clarence Mars in 1911 and is headquartered in McLean, VA.

Glanbia Nutritionals (Ireland) Ltd., part of Glanbia Plc, is a company headquartered in Kilkenny, Ireland. The firm manufactures natural cheese, processed cheese, cheese foods, cheese spreads, and cheese analogs. Brian Anthony Phelan is the current CEO, occupying that position since 2013.

RegeneRx is a publicly traded, clinical-stage, biopharmaceutical company engaged in the design, research and development of novel peptides targeted at diseases with unmet medical needs. RegeneRx’s mission is to research and develop novel pharmaceuticals that protect and repair tissue and organ damage caused by disease, trauma or other pathology. RegeneRx acquired the rights to a novel peptide from the NIH in 1999. This intellectual property for Thymosin Beta 4 (Tβ4) allowed the company to direct its focus on tissue protection and repair in multiple disease indications. RegeneRx’s management team is focused on moving three distinct Tβ4-based drug candidates through the clinic: RGN-137, RGN-259 and RGN-352. RegeneRx also holds over 60 issued patents or filed patent applications worldwide in order to enable and protect multiple indications and applications for its product candidates. In addition to Tβ4, RegeneRx is developing Tβ4 peptide fragments for cosmeceutical applications, separate and distinct from the pharmaceutical peptide and formulations. RegeneRx intends to pursue strategic business relationships to develop these smaller peptides for the cosmeceutical market.

Septodont Holding SAS manufactures dental pharmaceutical products. It process includes the final sterilization that ensures total security practitioner. The company was founded in 1932 and is headquartered in Saint-Maur-des-foss��s, France.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

W. L. Gore & Associates has made its name by creating innovative, technology-driven solutions, from medical devices that treat aneurysms to high-performance GORE‑TEX® fabrics. A privately held company with annual sales of more than $3 billion, Gore is committed to perpetuating its 50-plus year tradition of product innovation. Gore focuses its efforts in four main areas: electronics, fabrics, industrial and medical products. The company’s electronic products division develops and manufactures high-performance copper and optical signal transmission products. Gore’s fabrics provide protection from the elements and enable wearers to remain comfortable across a broad range of activities and conditions. The products made by Gore’s industrial division meet diverse contamination control and processing challenges throughout industry. Implants from the medical division provide creative healing solutions to complex medical problems. Today, Gore employs more than 10,000 employees, called associates, with manufacturing facilities in the United States, Germany, the United Kingdom, Japan and China, and sales offices around the world.

Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, multiple sclerosis, immunology, and oncology. They help people with debilitating and complex conditions that are often difficult to diagnose and treat. They are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Genzyme became part of Sanofi in 2011. While continuing to focus on rare diseases, they also established ourselves as a leader in the field of multiple sclerosis. In 2016, their focus expanded to include Sanofi’s programs in oncology and immunology. Their approach is shaped by a long history of developing highly specialized treatments and forging close relationships with physician and patient communities. Founded as Genzyme in Boston in 1981, they rapidly grew to become one of the world’s leading biotechnology companies, recognized for their pioneering development of treatments for rare genetic disorders and their innovative contributions to medical science and biomanufacturing.

Avacore Technologies, Inc. is an American private company located in Ann Arbor, MI, that manufactures and wholesales surgical and medical devices.

ONO Pharmaceutical is focused on the production, purchase, and sale of pharmaceuticals and diagnostic reagents on prescription pharmaceuticals. The company focuses on drug discovery leads that are high in certainty and globally competitive. The company was started in 1717 in Dosho-machi, Osaka. Throughout its 300-year history, ONO has dedicated itself to developing innovative and breakthrough pharmaceutical products.

VIVUS, Inc. engaged in the development and commercialization of novel therapeutic products. The firm’s products were indicated for the treatment of obese and overweight patients, exocrine pancreatic insufficiency, and erectile dysfunction. Its products include PANCREAZE, Qsymia, and STENDRA/SPEDRA. The company was founded by Virgil A. Place in April 16, 1991 and it was headquartered in Campbell, CA.

Ajinomoto Co. is a global manufacturer of high-quality seasonings, processed foods, beverages, amino acids, pharmaceuticals and specialty chemicals. For many decades Ajinomoto Co. has contributed to food culture and human health through wide-ranging application of amino acid technologies. Today, the company is becoming increasingly involved with solutions for improved food resources, human health and global sustainability. Founded in 1909 and now operating in 26 countries, Ajinomoto Co. had net sales of JPY 1,197.3 billion (USD 15.1 billion) in fiscal 2011. The Ajinomoto Group Standards of Business Conduct (hereinafter the "Standards of Conduct") describe the conduct that every member of the Ajinomoto Group must understand and practice every day in order to implement the Ajinomoto Group Philosophy in accordance with the Ajinomoto Group Way. The Standards of Conduct also represent the commitments made to all stakeholders by Ajinomoto Group companies. Ajinomoto aim to be "a group of companies that contributes to human health globally" by continually creating unique value to benefit customers. To become a global group of food companies centered on the world's No. 1 seasoning business. To become a global group of aminoscience companies that contributes to humankind with the world's No. 1 amino acid technology. To become a group of health-promoting companies with a scientific approach to good taste and health.

Boston Scientific Ltd., part of Boston Scientific Corp., is a British company located in Hemel Hempstead. The firm distributes medical products. It was founded in 1992.\nThe company says this about itself: Boston Scientific Ltd designed, manufactured and sold transvaginal mesh (“TVM”) medical devices that were implanted into thousands of Canadian women for the treatment of Stress Urinary Incontinence (“SUI”) and Pelvic Organ Prolapse (“POP”).

Boston Scientific Scimed, Inc. develops, manufactures, and markets medical devices used principally to treat cardiovascular disease.